NEO trades 47.5% below Wall Street's consensus target of $22.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NEO achieves its forward estimates and maintains a stable P/E multiple of 75.6x. This scenario reflects the blended consensus of 30 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, NeoGenomics, Inc. (NEO) has a Wall Street consensus price target of $22.50, based on estimates from 30 covering analysts. With the stock currently trading at $15.25, this represents a potential upside of +47.5%. The company has a market capitalization of $1.96B.
Analyst price targets range from a low of $19.00 to a high of $28.00, representing a 40% spread in expectations. The median target of $21.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 24 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NEO trades at a trailing P/E of -60.7x and forward P/E of 75.6x. Analysts expect EPS to grow +180.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CDNACareDx, Inc | $3.9B | $74.56 | $75.25 | +0.9% | Buy | 41.8x | 14 |
NTRANatera, Inc. | $41.2B | $287.47 | $393.16 | +36.8% | Buy | — | 28 |
LHLabcorp Holdings Inc. | $30.2B | $368.24 | $389.89 | +5.9% | Buy | 19.9x | 35 |
DGXQuest Diagnostics Incorporated | $28.3B | $256.35 | $256.17 | -0.1% | Hold | 22.7x | 34 |
MYRGMYR Group Inc. | $4.2B | $267.27 | $391.33 | +46.4% | Buy | 20.6x | 22 |
FLGTFulgent Genetics, Inc. | $688M | $24.21 | $19.00 | -21.5% | Buy | — | 9 |
PGNYProgyny, Inc. | $2.9B | $36.71 | $35.63 | -2.9% | Buy | 28.6x | 21 |
CGENCompugen Ltd. | $191M | $2.02 | $5.00 | +147.5% | Buy | — | 15 |
ILMNIllumina, Inc. | $30.7B | $202.61 | $252.73 | +24.7% | Buy | 37.4x | 50 |
TMOThermo Fisher Scientific Inc. | $255.2B | $686.79 | $694.27 | +1.1% | Buy | 27.2x | 43 |
Quick answers to the most common questions about buying NEO stock.
The consensus Wall Street price target for NEO is $22.5, representing 47.5% upside from the current price of $15.25. With 30 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NEO has a consensus rating of "Buy" based on 30 Wall Street analysts. The rating breakdown is predominantly bullish, with 24 Buy/Strong Buy ratings. The consensus 12-month price target of $22.5 implies 47.5% upside from current levels.
At a forward P/E of 75.5699x, NEO trades at a premium valuation. The consensus price target of $22.5 (47.5% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $28 for NEO, while the most conservative target is $19. The consensus of $22.5 represents the median expectation. These targets typically reflect 12-month expectations.
NEO is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 23 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NEO stock forecast based on 30 Wall Street analysts shows a consensus price target of $22.5, with estimates ranging from $19 (bear case) to $28 (bull case). The median consensus rating is "Buy".
NEO trades at a forward P/E ratio of 75.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NEO, with a "Buy" consensus rating and $22.5 price target (47.5% upside). 24 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NEO analyst price targets range from $19 to $28, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $22.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.